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Patterns of initiation of second generation
antipsychotics for bipolar disorder: a
month-by-month analysis of provider behavior
Christopher J Miller1*, Mingfei Li1,3†, Robert B Penfold4,5†, Austin F Lee1,3,6,7†, Eric G Smith1,8†, David N Osser9†,
Laura Bajor1† and Mark S Bauer1,2†
Abstract
Background: Several second generation antipsychotics (SGAs) received FDA approval for bipolar disorder in the
2000s. Although efficacious, they have been costly and may cause significant side effects. Little is known about the
factors associated with prescribers’ decisions to initiate SGA prescriptions for this condition.
Methods: We gathered administrative data from the Department of Veterans Affairs on 170,713 patients with
bipolar disorder between fiscal years 2003–2010. Patients without a prior history of taking SGAs were considered
eligible for SGA initiation during the study (n =126,556). Generalized estimating equations identified demographic,
clinical, and comorbidity variables associated with initiation of an SGA prescription on a month-by-month basis.
Results: While the number of patients with bipolar disorder using SGAs nearly doubled between 2003 and 2010,
analyses controlling for patient characteristics and the rise in the bipolar population revealed a 1.2% annual decline
in SGA initiation during this period. Most medical comorbidities were only modestly associated with overall SGA
initiation, although significant differences emerged among individual SGAs. Several markers of patient severity
predicted SGA initiation, including previous hospitalizations, psychotic features, and a history of other antimanic
prescriptions; these severity markers became less firmly linked to SGA initiation over time. Providers in the South
were somewhat more likely to initiate SGA treatment.
Conclusions: The number of veterans with bipolar disorder prescribed SGAs is rising steadily, but this increase
appears primarily driven by a corresponding increase in the bipolar population. Month-by-month analyses revealed
that higher illness severity predicted SGA initiation, but that this association may be weakening over time.
Keywords: Bipolar disorder, Antipsychotics, Veterans
Background
Bipolar disorder is associated with high morbidity, mortal-
ity, health care costs, and risk of suicide [1-3]. Beginning
in the 1960’s, lithium emerged as the frontline treatment
for this disorder [4], with anticonvulsants like carbamaze-
pine [5] and valproate [6] expanding the armamentarium.
More recently, several second-generation antipsychotics
(SGAs) have received FDA approval and guideline en-
dorsement for various phases of bipolar disorder including
mania, depression, and mixed states [7-10], with further
support from meta-analyses [11-14]. Some treatment
guidelines, in fact, go further in recommending SGAs as
frontline treatments for mania and bipolar depression
[15,16]. The number of annual SGA prescriptions for
bipolar disorder now rivals that written for lithium and
valproate combined [17]. However, several SGAs have
concerning cardiometabolic side effect profiles [18-21]
and they have been among the most costly classes of
medications in the U.S. [22].
Little research has investigated the factors affecting pro-
viders’ decisions to prescribe SGAs in this population.
Patient-based studies of mixed diagnostic groups have
found inconsistent results regarding impacts of patient
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gender [23-32], race [23-37], or age [23,25-29,31,32,35] on
SGA prescribing. Fewer studies have examined clinical
factors like substance use, cardiometabolic risk, or prior
treatment [23-25,27-30]. Crucially, only a small subset of
these studies [33,34] focused on bipolar disorder specific-
ally. More work is needed to identify the factors that affect
providers’ decisions to treat bipolar disorder with SGAs
in order to facilitate personalization of treatment and
system-level quality improvement interventions.
Accordingly, this study used national Department of
Veterans Affairs (VA) data to identify demographic and
clinical factors associated with the decision to initiate an
SGA for bipolar disorder from 2003–2010, and also to de-
termine whether SGAs have been used more broadly (i.e.
for less severely ill patients) over time. While our primary
analyses focused on SGAs as a group, we secondarily
investigated predictors of initiation for individual SGAs.
Our analyses were designed to assess patient characteris-
tics on a month-by-month basis, approximating the data
that a prescriber might have readily accessible in deciding
whether or not to prescribe an SGA.
Methods
The VA Central Institutional Review Board approved all
study procedures.
Population
We obtained administrative records from the VA Corporate
Data Warehouse for fiscal years 2003–2010. All VA service
users who received a diagnosis of bipolar disorder (ICD-9
code 296.xx, including bipolar type I, type II, and Not
Otherwise Specified [NOS]) at one inpatient or two out-
patient service contacts in a one-year period were included
in the study population. Individuals with any schizophrenia
spectrum diagnosis (290.0-298.9) at any point during the
study period were excluded.
From this overall sample (n = 170,713), we identified
on a month-by-month basis those patients “at risk” for
SGA initiation, defined as (a) not having received an
SGA prescription from the beginning of the study period
to the month in question (i.e., excluding those with any
prior SGA treatment from 2003 to that month), and (b)
having a clinical encounter for their bipolar disorder in
that month. To assess characteristics likely to impact
clinical decision-making at a given point in time, this
sample (n = 126,556 unique individuals) was then char-
acterized on a month-by-month basis regarding demo-
graphic and clinical characteristics and whether they had
initiated an SGA in that month, as defined below.
Preliminary analyses also explored the number of pro-
viders prescribing SGAs within VA. Providers “at risk”
for prescribing an SGA within a given month were de-
fined as clinicians from prescribing specialties (physician,
advanced practice nurse, physician’s assistant, PharmD)
who provided a bipolar disorder diagnosis for at least
one clinical encounter that month.
Definition of SGA initiation
SGA initiation, our primary outcome, was coded dichot-
omously each study month. Analyses focused on the five
most common oral SGAs used to treat bipolar disorder:
aripiprazole, olanzapine, quetiapine, risperidone, and
ziprasidone. Initial analyses investigated these medications
as a group; while additional analyses assessed individual
agents. Newer antipsychotics (paliperidone, iloperidone,
lurasidone, asenapine), approved after 2006, were not
included, nor was clozapine (due to very low prevalence
within VA) [38], or injectable antipsychotics (due to a lack
of adequate recording in VA administrative data).
Analyses focused on each patient’s first intentional trial
of an SGA during 2003–2010 [39]. Intentional trials were
defined as receipt of (a) at least one 30-day outpatient pre-
scription, or (b) at least three consecutive days of inpatient
administration. Thirty days was the modal duration for
outpatient prescriptions; sensitivity analyses reflected little
variation in usage based on this duration (e.g. only 6-8%
of outpatient SGA prescriptions were for <30 days). Those
initiating SGAs who were hospitalized for <3 days were
adequately identified by 30-day outpatient prescriptions at
discharge. We included any daily dose since prescribers
might start a medication at lower dosages before titrating.
For each month, patients were identified as SGA initia-
tors if they (a) had not received a previous intentional
SGA trial during the study period, and (b) received an
intentional trial that month for any of the five study SGAs.
The comparison group of SGA non-initiators for each
month was defined as all patients who (a) had not received
a previous intentional SGA trial during the study period,
(b) had been seen by a prescriber for bipolar disorder that
month, but who (c) did not receive a prescription for an
intentional SGA trial that month. For 2003 we began ana-
lyses at month seven, thus requiring at least a six-month
clean period for all patients.
Covariates
Demographics
Demographic characteristics included patient age, gender,
race/ethnicity, marital status, VA eligibility status (≥50%
VA service-connected pension, which relieves copays for
clinical services), and geographic region [40,41].
Clinical course variables
Bipolar type was dichotomized as bipolar type I versus bi-
polar type II/NOS, with bipolar I assigned if ≥10% of prior
diagnoses were bipolar I; sensitivity analysis indicated that
varying this cut-off from 10-50% resulted in little change
in proportion of type I versus II/NOS. Psychotic features
were identified for a given month if any diagnoses of mood
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episode with psychotic features (ICD-9 codes 296.×4) were
identified over the prior year. Treatment variables included
prescriptions of antidepressants and antimanic agents (lith-
ium, anticonvulsants, first-generation antipsychotics) within
the prior year. Prior hospitalization status was dichotomized
as any/no prior acute mental health inpatient hospitaliza-
tions since the beginning of the study.
Comorbidities
Based on published literature, comorbidities judged to po-
tentially affect provider decisions were coded as present if
the patient received treatment for a given diagnosis in the
12 months prior to the month in question. These included
substance use disorders, tobacco use disorder, anxiety
disorder, sleep disorders, traumatic brain injury, diabetes,
hyperlipidemia, cardiac dysrhythmia, and liver, kidney, or
thyroid disorders.
Establishing time-varying covariates
Some covariates (e.g. gender, race) were treated as time-
invariant. Others (e.g. age, clinical course variables, co-
morbidities) were assessed on a month-to-month basis.
This approach allowed us to characterize status for each
patient for each study month. For instance, consider a
hypothetical patient who was diagnosed as bipolar type I
in January, 2004, that the case is not referring to an ac-
tual patient developed diabetes in January, 2005, and ini-
tiated aripiprazole in June, 2005. For any month in 2004
in which he was treated for bipolar disorder, he would
qualify as an SGA non-initiator with bipolar type I. In
2005 he would remain a non-initiator, but would also
carry a diabetes diagnosis. In June of 2006 he would
qualify as an SGA initiator with bipolar type I and
diabetes, and during subsequent months would be
considered ineligible for initiator or non-initiator status.
Data analyses
We first calculated the annual number and rate of SGA
prescriptions in the bipolar population, as well as the
annual number and rate of providers writing SGA
prescriptions. We used preliminary time series analyses
to explore the overall change in these numbers over time.
Our primary analytic tool was multivariate generalized
linear modeling (GLM) with binomial distribution and
logit link function to determine rates and correlates of
SGA initiation on a month-by-month basis. Generalized
estimating equations (GEE) were used to account for
correlations from repeated measures within patients, as
an individual patient could be in the dataset at several
points as non-initiator before finally initiating an SGA in
a later month. This allowed us to aggregate data across
all 96 study months, accounting for patients appearing
in multiple consecutive or non-consecutive months as
described above. All variables were entered into the
model simultaneously. We then added predictor-by-time
interaction terms to the GLM to investigate changes
over time in SGA initiation rates for those with milder
versus more severe forms of bipolar disorder, specific-
ally: (a) bipolar type I versus II/NOS, (b) psychotic
features, (c) prior psychiatric hospitalization, and (d)
treatment with antimanic medications.
Finally, we used multinomial univariate regression
models to determine whether several comorbid condi-
tions, characterized on a month-by-month basis, were
associated with the choice of specific SGAs. The com-
parison drug for these analyses was aripiprazole, which
is associated with relatively mild cardiometabolic or
sedative effects [42]. If a patient initiated more than one
SGA, only their first initiation was included in these
latter analyses.
Results
Overall SGA use for bipolar disorder
The number of patients with bipolar disorder prescribed
SGAs almost doubled from 2003 to 2010 (31,779 in 2003;
61,697 in 2010; average annual increase of 4,226; 95% CI =
3,752-4,699; p < .0001), including both new initiators of
these medications as well as patients continuing previous
prescriptions. The number of patients treated for bipolar
disorder increased more modestly (53,591 in 2003; 85,684
in 2010). Accordingly, the proportion of bipolar patients
using an SGA rose from 59.3% in 2003 to a peak of 74.9%
in 2008, followed by a slight decrease to 72.0% in 2010
(Figure 1; average 7.1% per year, OR = 1.071, 95% CI =
1.068-1.074, p < .0001. This increase was matched by a rise
in the number of providers writing these prescriptions, ran-
ging from 11,031 in 2003 to a peak of 15,965 in 2009,
followed by a slight reduction to 15,609 in 2010 (average
annual increase 556; 95% CI = 365-747; p = .0007). All told,
out of our overall sample of 170,713 patients with bipolar
Figure 1 Percent of patients with bipolar disorder treated with
individual SGAs, 2003–2010.
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disorder, 113,510 had at least one SGA prescription written
during the study period (66%). While the number of
providers writing SGA prescriptions for bipolar disorder
increased, the proportion of eligible providers writing SGA
prescriptions decreased slightly over the course of the study
(from 90.2% in 2004 to 85.6% in 2010; annual OR = 0.927;
95% CI = 0.918-0.936; p < .0001).
There was heterogeneity in overall use of individual SGAs,
with significant average annual increases for aripiprazole
(2,910 users; 95% CI = 2,505-3,316; p < .0001), quetiapine
(2,427; 95% CI = 1,571-3,284; p = .0004), and ziprasidone
(534, 95% CI = 431-637; p < .0001), but a reduction for
olanzapine (861 fewer annual users; 95% CI = 438-1,284;
p = .0025) and no change for risperidone (138; 95% CI =
−111-386; p = .2232). In terms of proportion of users, annual
increases were seen for aripiprazole (OR= 1.408, 95% CI =
1.402-1.414), quetiapine (OR= 1.055, 95% CI = 1.052-1.057),
and ziprasidone (OR= 1.092, 95% CI = 1.086-1.098), with
decreases for olanzapine (OR = 0.832, 95% CI = 0.829-0.834)
and risperidone (OR= 0.934, 95% CI = 0.931-0.936) (all p <
0.0001).
SGA initiation in bipolar disorder
Figure 2 describes the nationwide number of patients newly
initiated on an SGA each year, indicating between 5,109
and 6,745 patients entering the population of SGA users
each year between 2004 and 2010 (mean = 5,951; 95% CI =
4,685-7,217; p < .0001). There was no significant change
over time in the number of new initiators per year (annual
average increase 11; 95% CI = −332-355; p = .9374). When
combined with the steady increase in the population of
patients with bipolar disorder, this meant that the odds of
being newly initiated on an SGA actually decreased as the
study progressed (annual OR 0.929; 95% CI = 0.924-0.933;
p < .0001).
Description of the patient sample and bivariate
comparisons
Table 1 summarizes the VA bipolar population (n = 170,713)
including individuals who ever (n = 45,389) or never (n =
81,167) initiated an SGA during the study period, yielding a
primary analytic sample of 126,556. The remaining 44,157
patients entered the study taking an SGA and so were
excluded from initiator analyses.
Unadjusted bivariate comparisons between SGA initiators
and non-initiators using all available data during the study
period (Table 1) demonstrated that nearly all characteristics
had small but statistically significant associations at the
p < .0001 level. Patients initiating an SGA during the study
period were on average several years younger than non-
initiators. Those initiated on an SGA were nearly twice as
likely to be identified as having psychotic features, but only
slightly more likely to have a bipolar type I diagnosis, sub-
stance use disorder, or anxiety disorder, with small, incon-
sistent impact of medical comorbidities. Patients initiated
on an SGA were more likely to have been hospitalized for a
psychiatric issue at least once and to receive a non-SGA
antimanic prescription at least once.
Month-by-month, multivariate correlates of SGA initiation
Table 2 presents GLM findings for which, in contrast to
Table 1, covariates were entered simultaneously into the
model, and were coded as present only if diagnosed simul-
taneously or within the year prior to the month of SGA ini-
tiation. Again, small but statistically significant differences
were demonstrated for most variables. Among stronger ef-
fects, female gender was associated with reduced likelihood
of initiating an SGA (OR= 0.846, 95% CI = 0.815-0.878), as
was disability status (OR = 0.740, 95% CI = 0.717-0.763).
Compared to the Northeast, patients seen in the South
were more likely to initiate an SGA (OR= 1.288, 95% CI =
1.245-1.332), and those in the West less likely (OR = 0.919,
95% CI = 0.886-0.953). Patients with psychotic features
were more likely to be initiated on an SGA (OR = 1.696,
95% CI = 1.520-1.891). Patients with a mood stabilizer pre-
scription in the past year were much less likely to initiate
an SGA than those who had not (OR = 0.620, 95% CI =
0.606-0.634), unlike the all-years analysis (Table 1). Patients
with a sleep disorder diagnosis were more likely to initiate
an SGA (OR= 1.555, 95% CI = 1.435-1.685). Most medical
comorbidities were only modestly associated with overall
SGA initiation rates in our sample. GLM indicated an aver-
age reduction in the odds of SGA initiation over time
(OR = 0.988 per year, 95% CI = 0.982-0.993. When we
added prior hospitalization to the model, it was also
strongly associated with SGA initiation (OR = 2.629,
95% CI = 2.546-2.713).
Figure 2 Patients with bipolar disorder initiating SGAs, 2004–2010.
Note: Figure 2 begins with 2004 since patients were not eligible to be
labeled as SGA initiators until month 7 of 2003; see Methods for details.
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The role of clinical complexity in SGA initiation rates
over time
We hypothesized a priori that SGAs were being initiated for
an increasingly diverse population over time. Variable-by-
time interaction terms for several indicators of severity
(selected a priori) were added to the GLM. These analyses
indicated that, over successive years, SGA initiation be-
came increasingly common for individuals with: type II/
NOS (beta = 0.0168, Z = 2.34, p = .0219), no antimanic
prescription in the past year (beta = 0.0396, Z = 7.98,
p < .0001), and no previous psychiatric hospitalization
(beta = 0.07, Z = 12.78, p < .0001), although not for those
without psychotic features (beta = 0.0168, Z = 0.83,
p = .4196). Taken together, these results indicate that,
over time, patients with less severe bipolar disorder (as
marked by an absence of previous hospitalizations,
Table 1 Description of the sample
Bipolar population
(N =170,713)a
Never initiated SGA during study period
(N =81,167, 64.1% of those eligible for
SGA initiation)
Ever initiated SGA during study period
(N =45,389, 35.9% of those eligible for
SGA initiation)
Variable Mean SD Mean SD Mean SD
Age at study entryb 50.3 13.3 51.6 13.6 48.3 13.0
N % N % N %
Gender (female) 24,076 14.1 10,804 13.3 6,954 15.3
Disability status ≥50%c,d 52,584 30.9 23,067 28.5 13,148 29.0
Marital statusd 76,315 44.9 34,786 43.3 18,265 40.5
Race/ethnicitye
White 127,742 82.2 60,381 83.0 34,425 82.6
African American 20,884 13.4 9,305 12.8 5,588 13.4
Hispanic 4,034 2.6 1,861 2.6 891 2.1
Other race/ethnicityc 2,684 1.7 700 1.0 455 1.1
Clinical/treatment coursed
Psychotic features 22,119 13.0 6,822 8.4 7,322 16.1
Bipolar type I (versus type II/NOS)f 145,128 85.0 68,344 84.2 40,283 88.8
Antidepressant prescription 139,807 81.9 55,920 68.9 34,969 77.0
Antimanic prescription 128,596 75.3 51,820 63.8 35,755 78.8
Any psychiatric hospitalization 64,117 37.6 23,284 28.7 21,330 47.0
Comorbiditiesd
Diabetes 42,517 24.9 20,679 25.5 10,138 22.3
Obesity 61,182 35.8 27,469 33.8 16,581 36.5
Hyperlipidemia 101,886 59.7 47,770 58.9 26,190 57.7
Substance abuse 79,658 46.7 33,202 40.9 23,280 51.3
Tobacco use disorder 86,311 50.6 37,406 46.1 24,182 53.3
Anxiety disorder 102,130 59.8 43,310 53.4 27,331 60.2
Sleep disorder 29,355 17.2 11,762 14.5 8,072 17.8
Cardiac dysrhythmia 19,600 11.5 9,509 11.7 4,827 10.6
Liver disorder 22,332 13.1 9,460 11.7 5,997 13.2
Kidney disorder 19,044 11.2 9,271 11.4 4,729 10.4
Thyroid disorderc 20,226 11.9 9,429 11.6 5,566 12.3
Traumatic brain injury 9,209 5.4 3,629 4.5 2,557 5.6
aIncludes data on those patients ineligible to be labeled as SGA initiator or SGA non-initiator (N = 44,157).
bUnless otherwise stated, all comparisons between the ever-initiated and never-initiated groups were p < .0001.
cFor these variables, comparison between the ever-initiated and never-initiated groups was p > .0001 (>50% disability status: p = .0385; other race/ethnicity:
p = .0120; thyroid disorder, p = .0006).
dUnless otherwise stated, these variables were coded as present if they occurred at any point during the study period.
eBased on smaller N, due to missing values for 9% of the sample.
fAt patient’s last available data during the study period.
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psychotic features, antimanic prescriptions, and bipolar
type I diagnoses) represented an increasing share of new
SGA initiations.
Association of comorbidities with specific SGAs
Consistent with a priori hypotheses, diabetes, obesity,
and hyperlipidemia were associated with decreased odds
of initiating olanzapine, quetiapine, or risperidone com-
pared to aripiprazole (ORs ranging from 0.352 to 0.856,
all p < .0003) (Table 3). Cardiac dysrhythmia was associ-
ated with a trend toward lower likelihood of initiating
ziprasidone (OR = 0.725, 95% CI = 0.505-1.042, p = .0825).
Individuals with substance use disorders were more likely
to initiate olanzapine (OR = 1.321, 95% CI = 1.230-1.417,
p < .0001) or quetiapine (OR = 1.363, 95% CI = 1.288-
1.442, p < .0001). Those with comorbid sleep disorder did
not significantly differ in use of any SGAs with the excep-
tion of risperidone (OR = 0.794, 95% CI = 0.654-0.965,
p = .0204).
Discussion
This study revealed several core findings. First, SGA use
for bipolar disorder is increasing within VA medical cen-
ters, with an average of about 6,000 new SGA initiations
Table 2 Results from GLM predicting SGA initiation
Variable Odds ratio 95% CI – lower 95% CI – upper p
Age (decade) 0.997 0.997 0.997 <.0001
Gender (female) 0.846 0.815 0.878 <.0001
≥ 50% disability status 0.740 0.717 0.763 <.0001
Marital status (married) 1.011 0.985 1.039 .4062
Race/ethnicitya
African American 1.068 1.024 1.114 .0021
Hispanic 0.989 0.901 1.087 .8222
Other race/ethnicity 1.096 0.964 1.246 .1614
Regionb
Midwest 0.991 0.955 1.028 .6221
South 1.288 1.245 1.332 <.0001
West 0.919 0.886 0.953 <.0001
Clinical/treatment factors in prior year
Psychotic features 1.696 1.520 1.891 <.0001
Bipolar type I (versus type II/NOS)c 0.968 0.935 1.003 .0736
Antidepressant prescription 0.903 0.882 0.924 <.0001
Antimanic prescription 0.620 0.606 0.634 <.0001
Comorbidities in prior year
Diabetes 0.919 0.882 0.957 <.0001
Obesity 0.958 0.913 1.004 .0739
Hyperlipidemia 0.991 0.960 1.023 .5860
Substance abuse 0.965 0.933 0.999 .0407
Tobacco use disorder 1.065 1.030 1.103 .0003
Anxiety disorder 1.082 1.051 1.114 <.0001
Sleep disorder 1.555 1.435 1.685 <.0001
Cardiac dysrhythmia 1.096 0.999 1.202 .0520
Liver disorder 1.145 1.079 1.214 <.0001
Kidney disorder 1.187 1.069 1.318 .0014
Thyroid disorder 1.021 0.956 1.089 .5372
Traumatic brain injury 1.109 0.944 1.303 .2068
Change per year 0.988 0.982 0.993 <.0001
aComparison: White.
bComparison: Northeast.
cPatient was labeled as bipolar type I for a given month if at least 10% of bipolar encounters to date were for bipolar type I. See text for details.
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each year. Time trends suggest that this growth rate was
remarkably steady from 2004 to 2010, with no year see-
ing fewer than 5,000 or more than 7,000 new initiations.
Given a roughly parallel increase in the overall bipolar
population treated within VA, the proportion of individ-
uals with bipolar disorder receiving an SGA prescription
in a given year rose from 59% in 2003 to 75% in 2008
with a slight decrease to 72% in 2010. These increases in
use may have in part been driven by recent treatment
guidelines that suggest SGAs as potential first-line treat-
ments for multiple phases of bipolar disorder [15,16].
This decrease in overall use after 2008 may in part re-
flect effects of toxicity warnings on prescribing practices
from the middle 2000’s [43]. Regarding specific SGAs,
use of aripiprazole, quetiapine, and ziprasidone increased
over time while use of olanzapine and risperidone
declined. Among providers with prescription privileges
treating patients with bipolar disorder, the proportion
using SGAs shrunk somewhat over the course of the
study (from 90% to 86%), though still encompasses the
vast majority of potential prescribers.
A novel innovation in these analyses is the use of
GLM techniques to investigate factors that affect pro-
vider decision-making on a month-by-month basis, to
focus on clinical data available to prescribing clinicians.
These analyses revealed that, while the number of new
initiators each year remained relatively steady, the odds
of initiating an SGA actually decreased slightly over the
course of the study (OR = .988 annually). Additionally,
two related factors emerged as key in predicting initi-
ation of SGAs. First, SGA initiation was more common
overall for patients who appeared more clinically com-
plex. Second, over time SGA use appeared to be spread-
ing to those with less complex clinical profiles.
SGA initiation more common for clinically complex
patients
Providers were more likely to initiate SGAs for patients
who were generally more psychiatrically ill at the time of
their prescription (i.e. more likely to have a history of
psychiatric hospitalization, recent psychotic features, or
recent sleep disorder diagnosis); this is consistent with
our finding that those who received an SGA also—at
some time during the study period—received another
antimanic (Table 1). However, on a month-by-month
basis, prescriptions of other antimanics were less likely
prior to initiation of SGAs. One interpretation is that
those not receiving SGAs were already effectively con-
trolled by a non-SGA medication. However, it is also
possible that SGAs are being increasingly utilized as
first-line treatments, bypassing other medications. De-
finitive answer awaits finer-grained treatment trajectory
analyses.
SGA initiation spreading to less clinically complex cases
Time trend analyses indicate that, even though SGA initi-
ation was more common for more complex cases as
above, there was a broadening over time of the use of
SGAs to include less clinically complex populations. Spe-
cifically, variable-by-time interaction terms indicated that
SGA initiation became increasingly common for those
with bipolar type II/NOS, those with no concurrent anti-
manic prescription, and those with no prior psychiatric
hospitalization. This suggests that over time VA providers
may have become increasingly comfortable prescribing
SGAs for less severe portions of the bipolar population,
though more provider-specific quantitative or qualitative
data will be needed to draw firm conclusions.
Other factors related to SGA initiation
Most patient demographic covariates showed only mod-
est associations with SGA initiation. African American
patients were somewhat more likely to be given an initial
SGA prescription during the study period compared to
Whites, which is broadly in line with another VA study
which found slightly but nonsignificantly higher rates of
SGA use among African Americans (52%) compared to
others (44%) with bipolar disorder [34]. Given evidence
from previous studies that racial differences in SGA
prescriptions may be closing [35], future studies should
Table 3 Multinomial regressions for initiation of individual SGAs, compared to aripiprazole
Olanzapine Quetiapine Risperidone Ziprasidone
Comorbidity in
the past year
Odds
ratio
CI –
lower
CI –
upper
p-
value
Odds
ratio
CI –
lower
CI –
upper
p-
value
Odds
ratio
CI –
lower
CI –
upper
p-
value
Odds
ratio
CI –
lower
CI –
upper
p-
value
Diabetes 0.477 0.428 0.531 <.0001 0.771 0.718 0.828 <.0001 0.856 0.789 0.929 .0002 1.05 0.939 1.174 .3945
Obesity 0.352 0.305 0.407 <.0001 0.657 0.602 0.716 <.0001 0.607 0.547 0.675 <.0001 1.109 0.974 1.262 .1181
Hyperlipidemia 0.686 0.632 0.744 <.0001 0.857 0.808 0.91 <.0001 0.838 0.781 0.898 <.0001 0.944 0.855 1.041 .2469
Substance
abuse
1.321 1.23 1.417 <.0001 1.363 1.288 1.442 <.0001 1.216 1.14 1.298 <.0001 0.987 0.896 1.088 .7917
Sleep disorder 0.860 0.695 1.065 .1666 1.158 0.991 1.353 .0655 0.794 0.654 0.965 .0204 1.05 0.809 1.362 .7140
Cardiac
dysrhythmia
1.422 1.137 1.778 .0020 0.971 0.800 1.179 .7690 1.116 0.9 1.385 .3166 0.725 0.505 1.042 .0825
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consider including race by time interaction terms in
their statistical analyses.
The effects of medical comorbidities on SGA initiation
appeared relatively small when results for all SGAs were
combined, which makes intuitive sense given the hetero-
geneity of cardiometabolic risk profiles among the SGAs
we studied. As expected, certain medical comorbidities
were associated with substantial differences in prescrib-
ing practices for specific SGAs. Notably, individuals with
preexisting diabetes, obesity, or hyperlipidemia were less
likely to receive those SGAs with more prominent car-
diometabolic effects (olanzapine, quetiapine and risperi-
done). Patients with substance abuse, in contrast, were
more likely to receive these drugs: the sedating effects of
these SGAs may be seen as desirable in treating patients
with substance abuse disorders in whom benzodiaze-
pines are considered inadvisable [39]. Contrary to expec-
tations, quetiapine was not statistically more likely to be
prescribed than aripiprazole for individuals with sleep
disorders. It should be noted, however, that providers
would only be likely to provide a sleep disorder diagno-
sis if a patient’s sleep troubles occurred independently of
their bipolar condition (e.g. sleep apnea), which may
reflect a complex population in whom sedating drugs
would be avoided.
Regional variation in SGA initiation after controlling
for covariates was marked by higher rates of SGA use in
the South. Veterans in this region of the country have
lower self-reported mental and physical quality of life
than other regions, perhaps reflecting poorer clinical
course or sociodemographic differences [40,44]. How-
ever, analyses both in this bipolar population and among
veterans with PTSD [39] indicate prominent regional
variation despite extensive control for demographic and
clinical characteristics. This finding may thus reflect
regional differences in provider practice patterns, com-
monly reported across many health domains [45].
Limitations
Although administrative data provided a very large
sample (n > 125,000 patients), it has the disadvantage of
relying upon clinicians’ diagnostic coding accuracy.
Some conditions (e.g. obesity, sleep disturbance) may
have been present and influenced treatment decisions
and yet not been coded by clinicians. Similarly, codes
for bipolar mixed episodes were not reliably utilized,
although patients suffering mixed manic and depressive
symptoms may be more responsive to SGAs than to
other antimanic medications [46-48]. Furthermore, we
could not include data on non-VA prescribing. In
addition, we opted to approach these analyses primarily
as class analyses, although we secondarily conducted a
priori analyses on specific SGAs and specific clinical
correlates. Our current analyses did not include data on
provider variables (e.g. demographics, academic affili-
ation, training background), but this is a clear direction
for future research. Finally, our primary comparison was
between patients initiating SGAs and those not initiat-
ing SGAs; we did not conduct additional analyses with
different comparison groups (e.g. patients initiating lith-
ium or other antimanics). Future research on SGA initi-
ation exploring provider-level variables and using these
other comparison groups would help shed further light
on prescribers’ initial medication decision for bipolar
disorder.
Conclusions
Increase in SGA initiation within VA appears to be driven
by an increase in the bipolar population rather than in-
creasing rates of use of these drugs. Our month-by-month
analyses, however, indicated that initiation rates are related
to three factors: clinical complexity, spread of SGAs to less
severe patients over time, and geographic variation that
cannot be accounted for by our extensive list of covariates.
Assessing the clinical appropriateness of SGA use is beyond
the scope of these analyses, and must be judged in the con-
text of the evolving clinical evidence base as applied to indi-
vidual patients at the time of specific treatment decisions.
However, the regional heterogeneity in particular suggests
that social [49] or administrative [50] factors may play a
role in the spread of SGAs for bipolar disorder. Thus, atten-
tion at the clinical, administrative, and policy levels may be
warranted to ensure that utilization of SGAs is driven
primarily by evidence and patient need rather than other
factors.
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